Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Spotify Technology (SPOT) Price & Performance

Eli Lilly And CoTrade
Spotify TechnologyTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Spotify Technology — how do they compare? Eli Lilly And Co trades at $1,225.5 (market cap $1.08T), while Spotify Technology trades at $490.59 (market cap $103.00B). The key difference: Eli Lilly And Co is far larger — about 10.5× Spotify Technology's market cap, and Eli Lilly And Co pays a 0.57% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.

LLYSPOT
Market Cap
$1.08T$103.00B
Sector
HealthMedia
52-Week High
$1.24K$738.53
52-Week Low
$639.43$412.75
Enterprise Value
$1.13T$92.70B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Spotify Technology

Spotify (SPOT) trades at $489.65, down 4.33% in the last session, amid mixed technical signals and strong fundamentals. The stock shows a bullish moving average trend but neutral oscillators, with key support at $487. Financially, revenue grew to $17.19B in 2025 with a net income margin of 12.87%, while recent news highlights initiatives like AI artist labeling to enhance transparency.

Outlook remains positive with a consensus price target of $598.20, implying 22% upside, driven by subscriber growth and margin expansion. Risks include competitive pressures and cost management, but analyst sentiment is bullish with 62% buy ratings, supporting long-term value for investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Spotify Technology

Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.

Read more on SPOT